/
Our First-in-class, breakthrough modifier gene therapy platform presents a potential paradigm shift in treating inherited retinal diseases and blindness diseases affecting millions across the globe. Our technology pipeline includes: Novel Modifier Gene Therapy Platform OCU400 - Based on the use of nuclear hormone receptors ("NHRs"), we believe our novel modifier gene therapy platform has the po…
$1.38
$0.03 (-2.13%)
Price from 7 days ago
The business is unprofitable at the operating level (-1425.70% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 8.8%, steady but not accelerating. Margins contracted 75.3pp, which offsets some of the top-line progress.
ROIC dropped from -78.91% to -104.33%, capital efficiency is deteriorating. Negative free cash flow of -$57M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$4M
▲ +8.8% YoY
Net Income (TTM)
-$72M
▼ -25.5% YoY
Op. Margin
-1483.85%
▼ -75.3pp YoY
ROIC
-144.77%
▼ -25.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$60M
▼ -25.5% YoY
Op. Cash Flow (TTM)
-$59M
▼ -35.2% YoY
Net Debt
$1M
Cash & Equiv.
$32M
3Y CAGR: +21.0%
Continue Research